Charles River Laboratories International, Inc. (CRL)

Market Cap	8.39B
Revenue (ttm)	4.03B
Net Income (ttm)	-69.23M
Shares Out	49.21M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	16.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	381,724
Open	170.07
Previous Close	167.03
Day's Range	167.69 - 172.21
52-Week Range	91.86 - 230.02
Beta	1.50
Analysts	Buy
Price Target	189.50 (+11.2%)
Earnings Date	Nov 5, 2025

About CRL

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 23, 2000
• Employees: 20,100
• Stock Exchange: NYSE
• Ticker Symbol: CRL
• Website: https://www.criver.com

Financial Performance

In 2024, CRL's revenue was $4.05 billion, a decrease of -1.92% compared to the previous year's $4.13 billion. Earnings were $10.30 million, a decrease of -97.83%.

Analyst Summary

According to 16 analysts, the average rating for CRL stock is "Buy." The 12-month stock price target is $189.5, which is an increase of 11.20% from the latest price.

Price Target

$189.5

(11.20% upside)

Analyst Consensus: Buy